Subject(s)
Antirheumatic Agents/adverse effects , Cardiomyopathies/chemically induced , Drug Eruptions/etiology , Hematologic Diseases/chemically induced , Hydroxychloroquine/adverse effects , Long QT Syndrome/chemically induced , Retinal Diseases/chemically induced , Acute Generalized Exanthematous Pustulosis/etiology , Agranulocytosis/chemically induced , Anemia, Aplastic/chemically induced , Betacoronavirus , COVID-19 , Coronavirus Infections/drug therapy , Dermatology , Erythema Multiforme/chemically induced , Humans , Leukopenia/chemically induced , Nausea/chemically induced , Off-Label Use , Pandemics , Pigmentation Disorders/chemically induced , Pneumonia, Viral/drug therapy , SARS-CoV-2 , Stevens-Johnson Syndrome/etiology , Thrombocytopenia/chemically induced , Urticaria/chemically induced , COVID-19 Drug TreatmentABSTRACT
The recent empirical use of hydroxychloroquine (HCQ) in coronavirus disease 2019 (COVID-19) revived the interest in its cardiac toxicity, increasingly sidelined over time. We aimed to assess and compare the profile of cardiac adverse drug reactions (CADRs) associated with HCQ before and during COVID-19. We performed a retrospective comparative observational study using the French Pharmacovigilance network database between 1985 and May 2020 to assess all postmarketing CADRs associated with HCQ notified before COVID-19 in its approved indications for lupus and rheumatoid arthritis (preCOV), and those concerning its empirical use in COVID-19 (COV). Eighty-five CADR in preCOV were compared with 141 CADRs in COV. The most common CADR of preCOV were cardiomyopathies (42.4%) and conduction disorders (28.2%), both statistically more frequent than in COV (P < 0.001). COV notifications significantly highlighted repolarization and ventricular rhythm disorders (78.0%, P < 0.001) as well as sinus bradycardias (14.9%, P = 0.01) as compared with preCOV. Estimated incidence of CADR was significantly higher among patients exposed to off-label use of HCQ in COVID-19 (2.9%) than before COVID-19 in its approved indications (0.01%, P < 0.001). The use of HCQ in COVID-19 sheds a new light on the spectrum of its cardiac toxicity. This fosters the value of a closer monitoring of all patients treated with HCQ, regardless of its indication, and the importance of an update of its summary of product characteristics.
Subject(s)
COVID-19 Drug Treatment , Cardiotoxicity/etiology , Hydroxychloroquine/adverse effects , SARS-CoV-2 , Adult , Aged , Cardiomyopathies/chemically induced , Female , Heart Conduction System/drug effects , Humans , Male , Middle Aged , Retrospective StudiesSubject(s)
Cardiomyopathies , Chloroquine/adverse effects , Lupus Erythematosus, Systemic , Neutropenia , Renal Insufficiency , Retinal Diseases , Cardiomyopathies/blood , Cardiomyopathies/chemically induced , Cardiomyopathies/pathology , Chloroquine/administration & dosage , Female , Humans , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/drug therapy , Lupus Erythematosus, Systemic/pathology , Middle Aged , Neutropenia/blood , Neutropenia/chemically induced , Neutropenia/pathology , Renal Insufficiency/blood , Renal Insufficiency/chemically induced , Renal Insufficiency/pathology , Retinal Diseases/blood , Retinal Diseases/chemically induced , Retinal Diseases/pathologyABSTRACT
More than 2,000,000 individuals worldwide have had coronavirus 2019 disease infection (COVID-19), yet there is no effective medical therapy. Multiple off-label and investigational drugs, such as chloroquine and hydroxychloroquine, have gained broad interest due to positive pre-clinical data and are currently used for treatment of COVID-19. However, some of these medications have potential cardiac adverse effects. This is important because up to one-third of patients with COVID-19 have cardiac injury, which can further increase the risk of cardiomyopathy and arrhythmias. Adverse effects of chloroquine and hydroxychloroquine on cardiac function and conduction are broad and can be fatal. Both drugs have an anti-arrhythmic property and are proarrhythmic. The American Heart Association has listed chloroquine and hydroxychloroquine as agents which can cause direct myocardial toxicity. Similarly, other investigational drugs such as favipiravir and lopinavir/ritonavir can prolong QT interval and cause Torsade de Pointes. Many antibiotics commonly used for the treatment of patients with COVID-19, for instance azithromycin, can also prolong QT interval. This review summarizes evidenced-based data regarding potential cardiac adverse effects due to off-label and investigational drugs including chloroquine and hydroxychloroquine, antiviral therapy, monoclonal antibodies, as well as common antibiotics used for the treatment of COVID-19. The article focuses on practical points and offers a point-of-care protocol for providers who are taking care of patients with COVID-19 in an inpatient and outpatient setting. The proposed protocol is taking into consideration that resources during the pandemic are limited.